Amoxicillin

Generic Name: Amoxicillin

Brand Names: Amoxil, Augmentin, Clavulin, Moxatag, Omeclamox, Prevpac, Talicia, Voquezna 14 Day Dualpak 20;500, Voquezna 14 Day Triplepak 20;500;500

Drug Type: Small Molecule

Chemical Formula: C_₁₆H_₁₉N_₃O_₅S

CAS Number: 26787-78-0

Unique Ingredient Identifier: 9EM05410Q9

Background: Amoxicillin, or BRL-2333, is a penicillin G derivative first described in the literature in 1972. Amoxicillin has similar activity to penicillin and ampicillin, but leads to higher serum concentrations than ampicillin.

Amoxicillin was granted FDA approval on 18 January 1974.

Indication: Amoxicillin alone is indicated to treat susceptible bacterial infections of the ear, nose, throat, genitourinary tract, skin, skin structure, and lower respiratory tract. Amoxicillin is given with calvulanic acid to treat acute bacterial sinusitis, community acquired pneumonia, lower respiratory tract infections, acute bacterial otitis media, skin and skin structure infections, and urinary tract infections. Amoxicillin is given with omeprazole in the treatment of Helicobacter pylori (H. pylori) infection.

Amoxicillin is used in combination with vonoprazan and clarithromycin as co-packaged triple therapy or in combination with vonoprazan as co-packaged dual therapy to treat H. pylori infection in adults.

Associated Conditions: Acute Bacterial Sinusitis (ABS), Acute Otitis Media (AOM), Bacterial Infections, Community Acquired Pneumonia (CAP), Duodenal ulcer caused by helicobacter pylori, Genitourinary tract infection, Helicobacter Pylori Infection, Lower Respiratory Tract Infection (LRTI), Peptic Ulcer With H. Pylori Infection, Sinusitis, Skin and Subcutaneous Tissue Bacterial Infections, Urinary Tract Infection, Acute, uncomplicated Gonorrhea, Ear, nose, and throat infections

Clinical Trials

A Controlled Human Pneumococcal Infection Model (PIM) Study

Not Applicable

Completed

Conditions: Streptococcus Pneumoniae Infection

Interventions: Biological: Sp_6B
Drug: Amoxicillin 500 mg

First Posted Date: 2022-05-04

Last Posted Date: 2023-02-22

Lead Sponsor: Radboud University Medical Center

Target Recruit Count: 20

Registration Number: NCT05361499

Locations: 🇳🇱
Radboudumc, Nijmegen, Netherlands

Outpatient Antibiotics Following Previable Rupture of Membranes (pPPROM) Between 18 0/7 and 22 6/7 Weeks Gestational Age

Phase 4

Recruiting

Conditions: Pregnancy Preterm
Pregnancy Prom
PROM, Preterm (Pregnancy)
PROM (Pregnancy)
Premat Rupture Membranes Preterm Unspec to Length of Time Between Rupture/Labor
Premature Birth

Interventions: Drug: Azithromycin Pill
Drug: Amoxicillin Pill

First Posted Date: 2022-04-26

Last Posted Date: 2025-04-22

Lead Sponsor: University Hospitals Cleveland Medical Center

Target Recruit Count: 88

Registration Number: NCT05345457

Locations: 🇺🇸
University Hospitals, Cleveland, Ohio, United States
🇺🇸
MetroHealth, Cleveland, Ohio, United States
🇺🇸
Cleveland Clinic, Cleveland, Ohio, United States

High Dose Dual Therapy vs Clarithromycin Triple Therapy for Treatment Naive H Pylori Infection in an Urban Population

Phase 4

Completed

Conditions: Helicobacter Pylori Infection

Interventions: Drug: Amoxicillin
Drug: Omeprazole
Drug: Clarithromycin

First Posted Date: 2022-04-22

Last Posted Date: 2023-02-01

Lead Sponsor: Icahn School of Medicine at Mount Sinai

Target Recruit Count: 112

Registration Number: NCT05342532

Locations: 🇺🇸
Mount Sinai Union Square Division of Digestive Diseases, New York, New York, United States

Phase 1 Study of the Pharmacokinetics of Amoxicillin in Pregnancy

Phase 1

Recruiting

Conditions: Pregnancy Related

Interventions: Drug: Amoxicillin

First Posted Date: 2022-04-04

Last Posted Date: 2025-04-08

Lead Sponsor: University of Alabama at Birmingham

Target Recruit Count: 20

Registration Number: NCT05309928

Locations: 🇺🇸
UAB, Birmingham, Alabama, United States

Absorption of Antibiotics With High Oral Bioavailability in Short-bowel Syndrome

Phase 1

Recruiting

Conditions: Short Bowel Syndrome
Infection, Bacterial

Interventions: Drug: Levofloxacin
Drug: Sulfamethoxazole trimethoprim
Drug: Ofloxacin
Drug: Amoxicillin

First Posted Date: 2022-03-31

Last Posted Date: 2024-08-29

Lead Sponsor: Central Hospital, Nancy, France

Target Recruit Count: 10

Registration Number: NCT05302531

Locations: 🇫🇷
CHRU Nancy, Vandœuvre-lès-Nancy, Lorraine, France

Susceptibility-Guided Therapy for Helicobacter Pylori Infection Treatment

Phase 4

Conditions: Helicobacter Pylori Infection

Interventions: Drug: Esomeprazole
Drug: Bismuth potassium citrate
Drug: Metronidazole
Drug: Clarithromycin
Drug: Levofloxacin
Drug: Amoxicillin
Drug: Tetracycline

First Posted Date: 2022-02-22

Last Posted Date: 2022-03-18

Lead Sponsor: Shanghai Zhongshan Hospital

Target Recruit Count: 388

Registration Number: NCT05250050

Locations: 🇨🇳
Renji Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai, Shanghai, China
🇨🇳
Huashan Hospital, Fudan University, Shanghai, Shanghai, China
🇨🇳
Zhongshan Hospital, Fudan University, Shanghai, Shanghai, China

Prophylactic Antibiotic Treatment in Hemodialysis

Not Applicable

Recruiting

Conditions: Hemodialysis

Interventions: Drug: Amoxicillin Clavulanic 500/125mg or placebo

First Posted Date: 2022-02-21

Last Posted Date: 2024-01-30

Lead Sponsor: Zealand University Hospital

Target Recruit Count: 800

Registration Number: NCT05248620

Locations: 🇩🇰
Rigshospitalet, Copenhagen, Capital Region, Denmark
🇩🇰
Herlev-Gentofte Hospital, Copenhagen, Capital Region, Denmark
🇩🇰
Aalborg University Hospital, Aalborg, North Region, Denmark

and more 4 locations

Helicobacter Pylori Eradication With Probiotics Combined With Triple Therapy Versus Bismuth-containing Quadruple Therapy

Phase 4

Completed

Conditions: Dyspepsia
Gastritis
Peptic Ulcer

Interventions: Drug: Clostridium butyricum capsule
Drug: esomeprazole
Drug: amoxicillin
Drug: Bismuth
Drug: Bacillus clotting
Drug: clarithromycin